Sphingosine-1-Phosphate Modulates Vascular Clotting Activity in Cardiovascular Disease

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Science Advances  https://doi.org/10.1126/sciadv.aea9826 
Dr. Marcel Benkhoff  et al.

Points

Researchers identified a novel vessel-wall antithrombotic mechanism driven by sphingosine-1-phosphate and endothelial thrombomodulin that inhibits blood clot formation.
Laboratory models demonstrated that sphingosine-1-phosphate activates S1P receptor 1 and phosphoinositide 3-kinase signaling pathways to up-regulate endothelial thrombomodulin expression.
In vivo animal studies proved that enhancing endothelial thrombomodulin reduced arterial thrombosis without altering baseline physiological bleeding times.
Clinical evaluation of 74 cardiovascular patients confirmed that higher plasma sphingosine-1-phosphate concentrations strongly correlated with lower circulating thrombin levels.
Modulating localized endothelial thrombomodulin expression offers a promising therapeutic alternative to standard blood thinners for patients with elevated bleeding risks.

Summary

This study evaluated the antithrombotic efficacy and cellular mechanism of sphingosine-1-phosphate (S1P) in mitigating arterial thrombosis through endothelial thrombomodulin (TM) up-regulation. Current primary antithrombotic therapies—such as platelet aggregation inhibitors and anticoagulants—effectively prevent arterial occlusion but directly disrupt hemostasis, thereby imposing significant systemic bleeding risks. Researchers sought to determine whether targeting S1P receptor 1 (S1PR1) signaling could activate local endothelial TM expression to prevent arterial thrombosis without compromising systemic hemostatic function.

In vitro and murine models demonstrated that S1P selectively up-regulates endothelial TM expression via an S1PR1 and phosphoinositide 3-kinase (PI3K) dependent signaling pathway. In flow-chamber experiments, S1P significantly reduced platelet adhesion on endothelial cells, whereas in endothelial-free conditions, S1P exerted no direct effect on platelet activation. In vivo murine models showed that exogenous S1P enhanced endothelial TM expression and reduced arterial thrombus formation without prolonging physiological bleeding time. Conversely, sphingosine kinase 1-deficient mice exhibiting low endogenous S1P levels demonstrated suppressed endothelial TM expression and enhanced thrombus formation, an effect fully reversed by exogenous TM administration.

Clinical translation was evaluated in an all-comer cohort of 74 patients with cardiovascular disease. Higher circulating S1P concentrations significantly correlated with lower plasma thrombin levels and reduced clotting activity. These findings demonstrate that S1P inhibits arterial thrombus formation via a localized, endothelium- and TM-dependent mechanism rather than direct systemic platelet inhibition. Targeting S1PR1-mediated endothelial TM up-regulation represents a novel therapeutic strategy to prevent acute myocardial infarction and ischemic stroke without elevating bleeding risks in high-risk patients.

Link to the article: https://www.science.org/doi/10.1126/sciadv.aea9826

References

Benkhoff, M., Mourikis, P., Knoop, B., Barcik, M., Huckenbeck, T., Al-Kassis, G., Schönfelder, L., Seel, J., Kreuz, F., Hering, M., Trojovsky, K., Wollnitzke, P., Kielb, J., Weber, J., Ulrych, T., Rauch, B. H., Pfeiler, S., Dannenberg, L., Gerdes, N., … Polzin, A. (2026). S1P receptor 1 signaling reduces arterial thrombosis via up-regulation of endothelial thrombomodulin expression. Science Advances, 12(30), eaea9826. https://doi.org/10.1126/sciadv.aea9826